Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
630 studies found for:    "Lymphoblastic lymphoma"
Show Display Options
Rank Status Study
1 Recruiting NHL16: Study For Newly Diagnosed Patients With Acute Lymphoblastic Lymphoma
Condition: Lymphoblastic Lymphoma
Interventions: Drug: Prednisone;   Drug: Vincristine;   Drug: Daunorubicin;   Drug: PEG-asparaginase;   Drug: Erwinia asparaginase;   Drug: Doxorubicin;   Drug: Cyclophosphamide;   Drug: Cytarabine;   Drug: Thioguanine;   Drug: Clofarabine;   Drug: Methotrexate;   Drug: Mercaptopurine;   Drug: Dexamethasone;   Drug: Hydrocortisone;   Drug: Etoposide
2 Unknown  Hyper-CVAD Treatment in Lymphoblastic Lymphoma
Condition: Lymphoblastic Lymphoma
Intervention:
3 Unknown  Safety and Efficacy of an Adult Acute Lymphoblastic Leukemia Chemotherapy for Adult Lymphoblastic Lymphoma
Condition: Lymphoblastic Lymphoma
Interventions: Drug: Prednisone, vincristine, daunorubicin , cyclophosphamide , L.-asparaginase, cytosine-arabinoside, methotrexate, etoposide;   Procedure: hematopoietic stem cell allograft
4 Recruiting Observational Controlled Clinical Trials, on Adult Patients With T-lymphoblastic Lymphoma Treated With Intensive Chemo/Radiotherapy or Intensive Chemotherapy Followed by Transplant. Evaluation of Clinical, Anatomy -Pathological Parameters
Condition: Lymphoblastic Lymphoma
Intervention: Other: Latest generation chemotherapies for T-LBL + transplant
5 Recruiting Chemotherapy With Liposomal Cytarabine CNS Prophylaxis for Adult Acute Lymphoblastic Leukemia & Lymphoblastic Lymphoma
Conditions: Acute Lymphocytic Leukemia;   Adult Lymphoblastic Lymphoma
Interventions: Drug: DNR;   Drug: VCR;   Drug: PEG-asp;   Drug: CTX;   Drug: Prednisone;   Drug: Liposomal AraC;   Drug: MTX;   Drug: LCV;   Drug: AraC;   Drug: Etoposide;   Drug: Dasatinib;   Drug: Rituximab;   Drug: Hydrocortisone
6 Active, not recruiting Augmented Berlin-Frankfurt-Munster (BFM) Therapy for Adolescent/Young Adults With Acute Lymphoblastic Leukemia or Acute Lymphoblastic Lymphoma
Conditions: Lymphoblastic Leukemia;   Lymphoblastic Lymphoma
Interventions: Drug: Daunorubicin;   Drug: Vincristine;   Drug: PEG-asparaginase;   Drug: Intrathecal Methotrexate;   Drug: Cyclophosphamide;   Drug: Cytarabine;   Drug: Mercaptopurine;   Drug: Methotrexate;   Drug: Doxorubicin;   Drug: Thioguanine
7 Recruiting Optimization of Therapy in Adult Patients With Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma by Individualised, Targeted and Intensified Treatment
Conditions: Acute Lymphoblastic Leukemia;   Lymphoblastic Lymphoma
Interventions: Drug: Rituximab;   Drug: Nelarabine;   Drug: PEG-Asparaginase;   Procedure: Cranial irradiation;   Drug: Imatinib;   Drug: Idarubicin;   Drug: Dexamethasone;   Drug: Cyclophosphamide;   Drug: Fludarabine;   Drug: Vincristine;   Drug: Mercaptopurine;   Drug: VP16;   Drug: Daunorubicin (DNR);   Drug: Methotrexate;   Procedure: Stem cell transplantation;   Drug: Cytarabine;   Drug: Vindesine;   Drug: Adriamycin;   Drug: Prednisolone
8 Active, not recruiting SC-PEG Asparaginase vs. Oncaspar in Pediatric Acute Lymphoblastic Leukemia (ALL) and Lymphoblastic Lymphoma
Conditions: Acute Lymphoblastic Leukemia;   Lymphoblastic Lymphoma
Interventions: Drug: SC-PEG;   Drug: Oncaspar
9 Completed German Multicenter Trial for the Treatment of Newly Diagnosed T-lymphoblastic Lymphoma in Adults
Condition: Lymphoma, Lymphoblastic
Interventions: Drug: Dexamethasone/Prednisolone;   Drug: Cyclophosphamide;   Drug: Vincristine;   Drug: Daunorubicin;   Drug: Asparaginase;   Drug: G-CSF;   Drug: Mercaptopurine;   Drug: Cytarabine;   Drug: Methotrexate;   Drug: VP16;   Drug: Vindesine;   Drug: Adriamycin;   Drug: Thioguanine;   Drug: HDARAC;   Procedure: CNS irradiation;   Procedure: Mediastinal irradiation;   Drug: Cladribine
10 Enrolling by invitation Acute Lymphoblastic Leukemia (ALL) and Lymphoblastic Lymphoma Gait Parameters Study
Conditions: Acute Lymphoblastic Leukemia;   Childhood Lymphoblastic Lymphoma
Intervention:
11 Recruiting Modified BFM-95 Regimen as First-Line Chemotherapy in Adults With T- Lymphoblastic Lymphoma
Condition: Lymphoma, Lymphoblastic
Interventions: Drug: induction;   Drug: protocol M;   Drug: maintenance therapy;   Drug: reinduction;   Drug: Intrathecal (IT)
12 Not yet recruiting BL-8040 and Nelarabine for Relapsed or Refractory T-Acute Lymphoblastic Leukemia/ Lymphoblastic Lymphoma
Conditions: T-Acute Lymphoblastic Leukemia;   Adult T Lymphoblastic Lymphoma
Interventions: Drug: BL-8040;   Drug: Nelarabine
13 Terminated A Dose Confirmation and Pharmacokinetic Study of Pegcrisantaspase Administered as Intravenous (IV) Infusion in Children and Young Adults With Acute Lymphoblastic Leukemia (ALL) /Lymphoblastic Lymphoma (LBL). Following Hypersensitivity to Pegaspargase (Oncaspar)
Conditions: Acute Lymphoblastic Leukemia;   Lymphoblastic Lymphoma
Intervention: Drug: pegcrisantaspase
14 Active, not recruiting Study to Evaluate the Safety and Tolerability of Weekly Intravenous (IV) Doses of BMS-906024 in Subjects With Acute T-cell Lymphoblastic Leukemia or T-cell Lymphoblastic Lymphoma
Conditions: Lymphoblastic Leukemia, Acute T-cell;   Precursor T-Cell Lymphoblastic Lymphoma
Interventions: Drug: BMS-906024;   Drug: Dexamethasone
15 Recruiting Hyper-CVAD Plus Nelarabine in Untreated T-ALL/Lymphoblastic Lymphoma
Conditions: Leukemia;   Lymphoblastic Lymphoma;   Leukemia, Lymphoblastic, Acute
Interventions: Drug: Doxorubicin;   Drug: Cyclophosphamide;   Drug: Cytarabine;   Drug: Dexamethasone;   Drug: Methotrexate;   Drug: Vincristine;   Drug: Nelarabine
16 Recruiting LBL-2016 for Children or Adolescents in China
Condition: Lymphoblastic Lymphoma
Interventions: Drug: Prednisone,Vincristine, Pegylated-asparaginase, Cytarabine, Cyclophosphamide, Daunorubicin, 6-mercaptopurine;   Drug: 6-mercaptopurine,Methotrexate;   Drug: Dexamethasone,Vincristine, Pegylated-asparaginase, Cytarabine, Cyclophosphamide, Doxorubicin, 6-mercaptopurine;   Drug: Dexamethasone,Vincristine, Pegylated-asparaginase, Cytarabine, Cyclophosphamide, Methotrexate;   Drug: Dexamethasone, Vindesine, Methotrexate, Ifosfamide, Daunorubicin, Pegylated-asparaginase;   Drug: Dexamethasone, Cytarabine, Etoposide, Pegylated-asparaginase;   Drug: Methotrexate, 6-mercaptopurine
17 Not yet recruiting Study of Standard Maintenance POMP/D Plus Ixazomib Maintenance Therapy in Adult Patients With Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma or Mixed Phenotype Acute Leukemia in Complete Remission (CR)
Conditions: Acute Lymphoblastic Leukemia in Complete Remission;   Lymphoblastic Lymphoma in Complete Remission;   Mixed Phenotype Acute Leukemia in Complete Remission
Interventions: Drug: Ixazomib;   Drug: Vincristine;   Drug: Dexamethasone/Prednisone;   Drug: Methotrexate (MTX);   Drug: 6-Mercaptopurine
18 Completed Treatment of Relapsed T-Cell Acute Lymphoblastic Leukemia or T-Lymphoblastic Lymphoma With MabCampath
Conditions: Adult Acute Lymphocytic Leukemia T-Cell;   Lymphoma, Lymphoblastic
Interventions: Drug: Alemtuzumab (MabCampath);   Drug: Cladribine
19 Recruiting Augmented Berlin-Frankfurt-Munster Therapy Plus Ofatumumab for Young Adults With Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
Conditions: Leukemia;   Precursor-B Acute Lymphoblastic Leukemia;   Lymphoblastic Lymphoma;   Lymphoma
Interventions: Drug: Cytarabine;   Drug: Daunorubicin;   Drug: Vincristine;   Drug: Prednisone;   Drug: PEG asparaginase;   Drug: Ofatumumab;   Drug: Rituximab;   Drug: Methotrexate;   Drug: Cyclophosphamide;   Drug: Mercaptopurine;   Drug: Doxorubicin;   Drug: Dexamethasone acetate;   Drug: Thioguanine
20 Withdrawn An Open-Label, Single-Arm, Multicenter Pharmacokinetic Study of Intramuscular Erwinaze® (Asparaginase Erwinia Chrysanthemi)/Erwinase® (Crisantaspase)
Condition: Acute Lymphoblastic Leukemia (ALL)/Lymphoblastic Lymphoma (LBL)
Intervention: Drug: Erwinaze® (Asparaginase Erwinia Chrysanthemi)/Erwinase® (Crisantaspase)

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.